Mentoring in Advanced mHealth Technologies and Machine Learning for HIV/Drug Abuse Research

指导艾滋病毒/药物滥用研究的先进移动医疗技术和机器学习

• 批准号: 10529984
• 负责人: Edward W Boyer
• 金额: $ 19.13万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-11-19 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10529984
• 关键词: Mentoring; Advanced; mHealth; Technologies; Machine

Abstract Renewal of my Midcareer Investigator Award in Patient-Oriented Research (K24) will allow me to continue my strong efforts directed toward successful original investigations and mentoring to generate research capacity in mobile technologies to improve health (mHealth). The impact of the initial K24 on my mentees has been striking. Since award of the initial K24, nearly two dozen of my mentees, 70% of whom are women or minorities, have been PI on NIH funded studies (under K, R, or Loan Repayment Program mechanisms). The impact the K24 on my own research has been substantial. Since 2014, I have been Principal Investigator (PI) on six federally funded awards: 1) one newly funded 4-year R01 from NIDA; 2) one R56 from NIDA; 3) one two-year R01 from NIDA; 4) one 4-year R01 from NIDA; 5) my K24 from NIDA; and 6) one newly funded 4-year DARPA research award. In addition, I received a William J Fulbright Foreign Scholarship to Malaysia. As my K24 evolved, so has my research focus. My overall research objective is to devote sufficient time to investigate use of next generation (“NextGen”) technologies, invisible biosensing, and machine learning in substance abuse and HIV research. My first research project, Virya, uses “digital phenotyping” with invisible biosensing and machine learning, to identify acute pain exacerbations in HIV+ individuals on opioids, a population at risk for problematic opioid use. The second reseach project uses mobile technologies to diagnose Covid-19 infection in HIV+ persons who inhale cannabis, itself a high-impact topic. Finally, the R01-funded MyTPill project compares the NextGen technology of unobtrusive ingestible biosensors that provide vivid, indisputable measures of medication ingestion. NextGen research discoveries become commercial products, but this process of introducing new discoveries into the healthcare economy remains deeply unfamiliar—yet increasingly important— to academic clinician-scientists. The objective of my Career Development Activities, therefore, involves learning how to navigate regulatory processes, FDA approvals, valuations, venture capital, contracts and intellectual property rights. Because of the growing importance of commercialization of research findings to the health and sustainability of academic careers, my overall mentoring objective of this K24 is to develop researchers who not only have the skills to conduct rigorous NextGen mHealth studies, but also to extend the mass of NIH-funded mHealth research into the healthcare economy. My mentoring approach incorporates several components that contributed to the success of my initial K24: dedicated funding for mentee’s early investigations; outstanding institutional support; several sources of referral of high-quality mentees; and renowned co- mentors who will help me establish a pipeline of mentees that have risen to that “cutting edge” where successful academic careers begin. This proposed K24 renewal, with its focus on NextGen technologies, invisible biosensing, and machine learning, is highly relevant to NIH’s mission because the lessons learned from this substance abuse and HIV research are directly applicable to the care of patients with common, intractable, and expensive conditions.

抽象的 续签以患者为导向的研究 (K24) 中的职业中期研究员奖将使我能够继续努力 旨在成功进行原创调查和指导，以产生移动技术的研究能力 改善健康（移动医疗）。最初的 K24 对我的学员的影响是惊人的。自从授予最初的 K24 以来， 我的近两打学员（其中 70% 是女性或少数族裔）是 NIH 资助的研究（在 K、R、 或贷款偿还计划机制）。 K24 对我自己的研究产生了巨大的影响。自2014年以来，我 曾担任六项联邦资助奖项的首席研究员 (PI)：1) 一项新资助的 NIDA 4 年期 R01 项目； 2）1个R56 来自 NIDA； 3) NIDA 的一份两年期 R01； 4) NIDA 4年R01 1个； 5）我的NIDA K24； 6) 一项新资助的 4 年 DARPA 研究奖。此外，我还获得了马来西亚威廉·J·富布赖特外国奖学金。作为我的K24 进化了，我的研究重点也随之变化了。我的总体研究目标是投入足够的时间来调查下一步的使用 新一代（“NextGen”）技术、隐形生物传感以及药物滥用和艾滋病毒研究中的机器学习。我的 第一个研究项目 Virya 使用“数字表型”和隐形生物传感和机器学习来识别急性疼痛 HIV+ 个体服用阿片类药物后病情加重，这些人群存在阿片类药物使用问题的风险。第二个研究项目 使用移动技术诊断吸入大麻的 HIV+ 患者的 Covid-19 感染，这本身就是一个高影响力的话题。 最后，R01 资助的 MyTPill 项目比较了不引人注目的可摄入生物传感器的 NextGen 技术，该技术提供 生动、无可争议的药物摄入测量。 NextGen 研究发现成为商业产品，但这 将新发现引入医疗保健经济的过程仍然非常陌生，但却越来越重要 学术临床医生科学家。因此，我职业发展活动的目标包括学习如何 浏览监管流程、FDA 批准、估值、风险投资、合同和知识产权。因为 研究成果的商业化对于学术生涯的健康和可持续性越来越重要，我的 K24 的总体指导目标是培养不仅具备进行严格的 NextGen 技能的研究人员 移动医疗研究，同时还将 NIH 资助的大量移动医疗研究扩展到医疗保健经济。我的指导 该方法包含了促成我最初的 K24 成功的几个组成部分： 早期调查；出色的机构支持；高质量受训者的推荐来源；以及知名合作伙伴 导师将帮助我建立一个受指导者的管道，这些受训者已经上升到成功学术的“前沿” 职业生涯开始。这项 K24 更新提案的重点是下一代技术、隐形生物传感和机器 学习，与 NIH 的使命高度相关，因为从药物滥用和艾滋病毒研究中吸取的教训 直接适用于常见、疑难、昂贵病症患者的护理。